Evidence map›Paper›PMID 33999405›Full record

ArticleCancer2021

Racial differences in the treatment and outcomes for prostate cancer in Massachusetts.

Alexander P Cole, Peter Herzog, Hari S Iyer, Maya Marchese, Brandon A Mahal, Stuart R Lipsitz, Joshua Nyambose, Susan T Gershman, Mark Kennedy, Gail Merriam and 2 more

Open access · greenAbstract read
In one paragraph

Article in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Alexander P ColeDivision of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-0049-8529
Peter HerzogDivision of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Hari S IyerDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-7596-9049
Maya MarcheseDivision of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Brandon A MahalDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-5406-3232
Stuart R LipsitzCenter for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Joshua NyamboseMassachusetts Department of Public Health, Boston, Massachusetts.
Susan T GershmanMassachusetts Department of Public Health, Boston, Massachusetts.
Mark KennedyBoston Public Health Commission, Boston, Massachusetts.
Gail MerriamMassachusetts Department of Public Health, Boston, Massachusetts.
Timothy R RebbeckDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-4799-1900
Quoc-Dien TrinhDivision of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-3857-9276
Brigham and Women's Hospital · USHarvard University · USMassachusetts Department of Public Health · USBoston Public Health Commission · US

Funding

Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Conquer Cancer Foundation 10202Defense Health AgencyNCI NIH HHS T32 CA009001NIH HHS T32 CA 009001Prostate Cancer Foundation 16YOUN20
6 · The paper itself

Abstract

backgroundMassachusetts is a northeastern state with universally mandated health insurance since 2006. Although Black men have generally worse prostate cancer outcomes, emerging data suggest that they may experience equivalent outcomes within a fully insured system. In this setting, the authors analyzed treatments and outcomes of non-Hispanic White and Black men in Massachusetts.

methodsWhite and Black men who were 20 years old or older and had been diagnosed with localized intermediate- or high-risk nonmetastatic prostate cancer in 2004-2015 were identified in the Massachusetts Cancer Registry. Adjusted logistic regression models were used to assess predictors of definitive therapy. Adjusted and unadjusted survival models compared cancer-specific mortality. Interaction terms were then used to assess whether the effect of race varied between counties.

resultsA total of 20,856 men were identified. Of these, 19,287 (92.5%) were White. There were significant county-level differences in the odds of receiving definitive therapy and survival. Survival was worse for those with high-risk cancer (adjusted hazard ratio [HR], 1.50; 95% CI, 1.4-1.60) and those with public insurance (adjusted HR for Medicaid, 1.69; 95% CI, 1.38-2.07; adjusted HR for Medicare, 1.2; 95% CI, 1.14-1.35). Black men were less likely to receive definitive therapy (adjusted odds ratio, 0.78; 95% CI, 0.74-0.83) but had a 17% lower cancer-specific mortality (adjusted HR, 0.83; 95% CI, 0.7-0.99).

conclusionsDespite lower odds of definitive treatment, Black men experience decreased cancer-specific mortality in comparison with White men in Massachusetts. These data support the growing body of research showing that Black men may achieve outcomes equivalent to or even better than those of White men within the context of a well-insured population. LAY SUMMARY: There is a growing body of evidence showing that the excess risk of death among Black men with prostate cancer may be caused by disparities in access to care, with few or no disparities seen in universally insured health systems such as the Veterans Affairs and US Military Health System. Therefore, the authors sought to assess racial disparities in prostate cancer in Massachusetts, which was the earliest US state to mandate universal insurance coverage (in 2006). Despite lower odds of definitive treatment, Black men with prostate cancer experience reduced cancer-specific mortality in comparison with White men in Massachusetts. These data support the growing body of research showing that Black men may achieve outcomes equivalent to or even better than those of White men within the context of a well-insured population.

Indexed as

Prostatic NeoplasmsWhite PeopleAdultAgedBlack or African AmericanHealthcare DisparitiesHumansMaleMassachusettsMedicareRace FactorsTreatment OutcomeUnited StatesYoung Adultprostate cancerracial disparitiessurgical outcomes

Identifiers

PMID33999405
PMCPMC9107927
OpenAlexW3163357799

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.